Use of monoclonal antibody therapy for nosocomial SARS-CoV-2 infection in patients at high risk for severe COVID-19: experience from a tertiary-care hospital in Germany
Authors:
- Johanna KoehlerJKJohanna Koehler
- Barbara RitzerBRBarbara Ritzer
- Simon WeidlichSWSimon Weidlich
- Friedemann GebhardtFGFriedemann Gebhardt
- Chlodwig KirchhoffChlodwig Kirchhoff
- Jens GemptJGJens Gempt
- Christiane QuerbachCQChristiane Querbach
- Dieter HoffmannDHDieter Hoffmann
- Bernhard HallerBHBernhard Haller
- Roland M. SchmidRSRoland M. Schmid
- Jochen SchneiderJSJochen Schneider
- Christoph D. SpinnerCSChristoph D. Spinner
Open Access
- 9 July 2021
- journal article
- research article
- Published by Springer Nature in Infection
- Vol. 49 (6) , 1313-1318
Abstract
Additional treatment options for coronavirus disease (COVID-19) are urgently needed, particularly for populations at high risk of severe disease. This cross-sectional, retrospective study characterized the outcomes of 43 patients with nosocomial severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection with and without treatment using monoclonal SARS-CoV-2 spike antibodies (bamlanivimab or casirivimab/imdevimab). Our results indicate that treatment with monoclonal antibodies results in a significant decrease in disease progression and mortality when used for asymptomatic patients with early SARS-CoV-2 infection.Keywords
Funding Information
- Klinikum rechts der Isar der Technischen Universität München
This publication has 9 references indexed in Scilit:
- Whole-Genome Sequencing Surveillance and Machine Learning of the Electronic Health Record for Enhanced Healthcare Outbreak DetectionClinical Infectious Diseases, 2021
- Real-World Experience of Bamlanivimab for Coronavirus Disease 2019 (COVID-19): A Case-Control StudyClinical Infectious Diseases, 2021
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodiesCell, 2021
- A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysisPLOS ONE, 2021
- Dexamethasone in Hospitalized Patients with Covid-19New England Journal of Medicine, 2021
- Prospective mapping of viral mutations that escape antibodies used to treat COVID-19Science, 2021
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19New England Journal of Medicine, 2021
- Remdesivir for the Treatment of Covid-19 — Final ReportNew England Journal of Medicine, 2020